• 1
    Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J 1981;283: 57781.
  • 2
    Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329: 13838.
  • 3
    Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103: 58893.
  • 4
    Kurlemann G, Benner T, Brämswig HJ. Adult height and target height in 111 boys and 98 girls treated for epilepsy during childhood. J Child Neurol 1997;12: 5135.
  • 5
    Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42: 11417.
  • 6
    Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14: 4905.
  • 7
    Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45: 44450.
  • 8
    Isojärvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39: 57984.
  • 9
    Isojärvi JI, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43: 44651.
  • 10
    Eiris J, Novo-Rodriguez MI, Del Rio M, et al. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000;41: 17.
  • 11
    Verrotti A, Basciani F, Domizio S, et al. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998;19: 3647.
  • 12
    Sözüer DT, Atakil D, Dogu O, et al. Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr 1997;156: 5657.
  • 13
    Serdaroglu G, Kurul S, Tutuncuoglu S, et al. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003;28: 3741.
  • 14
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30: 38999.
  • 15
    Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990;32: 21320.
  • 16
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499502.
  • 17
    Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998;24: 32355.
  • 18
    Sorva R, Lankinen S, Tolppanen EM, et al. Variation of growth in height and weight of children, II: after infancy. Acta Paediatr Scand 1990;79: 498506.
  • 19
    Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43: 148892.
  • 20
    Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127: 25662.
  • 21
    Macardle BM, McGowan ME, Greene SA, et al. Anticonvulsant drugs, growth, and development. Arch Dis Child 1987;62: 6157.
  • 22
    Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 2003;18: 1339.
  • 23
    Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28: 1269.
  • 24
    Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24: 2404.
  • 25
    Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis 1998;140: 199270.
  • 26
    National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000;160: 898904.
  • 27
    Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17: 78191.
  • 28
    Pylvänen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43: 5147.
  • 29
    Luef GJ, Lechleitner M, Bauer G, et al. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55: 538.
  • 30
    Isojärvi JI, Pakarinen AJ, Rautio A, et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994;35: 121720.
  • 31
    Isojärvi JI, Pakarinen AJ, Myllylä VV. Serum lipid levels during carbamazepine medication: a prospective study. Arch Neurol 1993;50: 5903.
  • 32
    Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine. Eur J Clin Pharmacol 1990;39: 1878.